RegulatoryApr 7, 2026, 06:41 AM
Nuvalent Submits New Drug Application to FDA for Neladalkib in Advanced ALK-Positive Non-Small Cell Lung Cancer
AI Summary
Nuvalent has submitted a New Drug Application (NDA) to the FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This submission marks a significant regulatory milestone for Nuvalent and could lead to a new treatment option for patients with this specific type of lung cancer, potentially impacting the company's future revenue and market position.
Key Highlights
- Nuvalent submitted an NDA to the FDA for neladalkib.
- Neladalkib targets advanced ALK-positive non-small cell lung cancer.
- The drug is intended for patients who have been pre-treated with tyrosine kinase inhibitors.